Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Global Immunoglobulins Market: Introduction | 11 | 2 |
| Overview | 11 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Global Immunoglobulins Market: Market Overview | 13 | 8 |
| Introduction | 13 | 1 |
| Rising Demand for Immunoglobulins Attributed to New Indications | 14 | 1 |
| On-Label Uses versus Off-Label Uses in the US | 15 | 1 |
| IVIG vs. SCIG Usage | 15 | 1 |
| Revenue Forecasts for the Global Immunoglobulins Market | 16 | 2 |
| Annual Cost of Therapy | 18 | 1 |
| Immunoglobulins Market Drivers and Restraints | 19 | 1 |
| Immunoglobulins Market Drivers | 20 | 1 |
| Increasing Off-Label Uses Pushing Market for Immunoglobulins | 20 | 1 |
| Neuroimmunologic Diseases Such as CIDP, MMN and GBS are Significant Growth Drivers | 20 | 1 |
| Awareness Drives in Europe Regarding PID May Push Growth | 20 | 1 |
| Immunoglobulins Market Restraints | 20 | 1 |
| Consolidation in Plasma Fractionation Facilities Represent Significant Barriers to Entry for Smaller Players | 20 | 1 |
| Limited Market Potential | 20 | 1 |
| Global Immunoglobulins Market: Geographical Landscape | 21 | 8 |
| Geographical Break-up | 21 | 1 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Therapy | 23 | 1 |
| Top Five Countries in Europe | 24 | 1 |
| Revenue | 24 | 2 |
| Annual Cost of Therapy | 26 | 1 |
| Japan | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Therapy | 28 | 1 |
| Global Immunoglobulins Market: Therapeutic Landscape | 29 | 58 |
| Primary Immunodeficiency | 29 | 1 |
| Introduction | 29 | 1 |
| Revenue | 30 | 2 |
| Annual Cost of Therapy | 32 | 1 |
| Epidemiology | 33 | 1 |
| Diseased Population | 34 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 35 | 1 |
| Treated Population | 35 | 1 |
| Current Use | 36 | 1 |
| Current Use of Immunoglobulins | 36 | 1 |
| Current Use of Other Therapies | 36 | 1 |
| Geographical Segmentation | 37 | 2 |
| Guillain-Barr Syndrome Market | 39 | 1 |
| Introduction | 39 | 1 |
| Revenue | 40 | 1 |
| Annual Cost of Therapy | 41 | 1 |
| Epidemiology | 42 | 1 |
| Diseased Population | 43 | 1 |
| Treatment Seeking Population | 43 | 1 |
| Diagnosed Population | 43 | 1 |
| Treated Population | 44 | 1 |
| Current Use | 44 | 1 |
| Current Use of Immunoglobulin | 44 | 1 |
| Current Use of Other Therapies | 45 | 1 |
| Geographical Segmentation | 45 | 2 |
| Chronic Lymphocytic Leukemia Market | 47 | 1 |
| Introduction | 47 | 1 |
| Revenue | 48 | 1 |
| Annual Cost of Therapy | 49 | 1 |
| Epidemiology | 50 | 1 |
| Diseased Population | 51 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosed Population | 52 | 1 |
| Treated Population with CLL Therapeutics | 52 | 1 |
| Treated Population with IVIG | 53 | 1 |
| Current Use | 54 | 1 |
| Current Use of Immunoglobulins | 54 | 1 |
| Current Use of Other Therapies | 54 | 1 |
| Geographical Segmentation | 55 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy Market | 56 | 1 |
| Introduction | 56 | 1 |
| Revenue | 57 | 1 |
| Annual Cost of Therapy | 58 | 1 |
| Epidemiology | 59 | 1 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 60 | 1 |
| Diagnosed Population | 60 | 1 |
| Treated Population | 60 | 1 |
| Current Use | 61 | 1 |
| Current Use of Immunoglobulins | 61 | 1 |
| Current Use of Other Therapies | 61 | 1 |
| Geographical Segmentation | 62 | 1 |
| Myasthenia Gravis Market | 63 | 1 |
| Introduction | 63 | 1 |
| Revenue | 64 | 1 |
| Annual Cost of Therapy | 65 | 1 |
| Epidemiology | 66 | 1 |
| Diseased Population | 67 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosed Population | 67 | 1 |
| Treated Population | 68 | 1 |
| Current Use | 68 | 1 |
| Current Use of Immunoglobulins | 68 | 1 |
| Current Use of Other Therapies | 68 | 1 |
| Geographical Segmentation | 69 | 1 |
| Multifocal Motor Neuropathy Market | 70 | 1 |
| Introduction | 70 | 1 |
| Revenue | 71 | 1 |
| Annual Cost of Therapy | 72 | 2 |
| Epidemiology | 74 | 2 |
| Diseased Population | 76 | 1 |
| Treatment Seeking Population | 76 | 1 |
| Diagnosed Population | 76 | 1 |
| Treated Population | 77 | 1 |
| Current Use | 77 | 1 |
| Current Use of Immunoglobulins | 77 | 1 |
| Current Use of Other Therapies | 77 | 1 |
| Geographical Segmentation | 78 | 1 |
| Idiopathic Thrombocytopenic Purpura | 79 | 1 |
| Introduction | 79 | 1 |
| Revenue | 80 | 1 |
| Annual Cost of Therapy | 81 | 1 |
| Epidemiology | 82 | 1 |
| Diseased Population | 83 | 1 |
| Treatment Seeking Population | 83 | 1 |
| Diagnosed Population | 84 | 1 |
| Treated Population | 84 | 1 |
| Current Use of Immunoglobulins and Other Therapies | 85 | 1 |
| Geographical Segmentation | 85 | 2 |
| Global Immunoglobulins Market: Pipeline Analysis | 87 | 2 |
| Research and Development Pipeline CIDP | 87 | 1 |
| Research and Development Pipeline PID | 87 | 1 |
| Research and Development Pipeline GBS | 88 | 1 |
| Research and Development Pipeline ITP | 88 | 1 |
| Research and Development Pipeline Myasthenia Gravis | 88 | 1 |
| Research and Development Pipeline Multifocal Motor Neuropathy | 88 | 1 |
| Research and Development Pipeline CLL | 88 | 1 |
| Global Immunoglobulins Market: Profiles of Marketed Products | 89 | 11 |
| Privigen | 89 | 1 |
| Overview | 89 | 1 |
| Approved Indications | 89 | 1 |
| Safety | 89 | 1 |
| Primary Humoral Immunodeficiency | 89 | 1 |
| Chronic ITP | 89 | 1 |
| Efficacy | 89 | 1 |
| Treatment of Primary Humoral Immunodeficiency | 89 | 1 |
| Treatment of Chronic ITP | 90 | 1 |
| Clinical Study Details | 90 | 1 |
| Gammagard S/D | 90 | 1 |
| Overview | 90 | 1 |
| Approved Indications | 90 | 1 |
| Safety | 91 | 1 |
| Efficacy | 91 | 1 |
| Treatment of Primary Immunodeficiency Diseases | 91 | 1 |
| Treatment of B-cell CLL | 91 | 1 |
| Treatment of ITP | 91 | 1 |
| Treatment of Kawasaki Syndrome | 91 | 1 |
| Gammagard Liquid | 91 | 1 |
| Overview | 91 | 1 |
| Approved Indications | 92 | 1 |
| Safety | 92 | 1 |
| Efficacy | 92 | 1 |
| Clinical Study Details | 92 | 1 |
| Octagam 5% | 92 | 1 |
| Overview | 92 | 1 |
| Approved Indications | 93 | 1 |
| Safety | 93 | 1 |
| Efficacy | 93 | 1 |
| Flebogamma 5% | 93 | 1 |
| Overview | 93 | 1 |
| Safety | 93 | 1 |
| Efficacy | 94 | 1 |
| Flebogamma 10% | 94 | 1 |
| Overview | 94 | 1 |
| Safety | 94 | 1 |
| Efficacy | 94 | 1 |
| Gamunex | 95 | 1 |
| Overview | 95 | 1 |
| Safety | 95 | 1 |
| Efficacy | 95 | 1 |
| Treatment of Primary Humoral Immunodeficiency by the Intravenous Route | 95 | 1 |
| Treatment of ITP | 96 | 1 |
| Treatment of CIDP | 96 | 1 |
| Gammaplex | 96 | 1 |
| Overview | 96 | 1 |
| Safety | 96 | 1 |
| Efficacy | 97 | 1 |
| Clinical Study Details | 97 | 1 |
| Vivaglobin | 97 | 1 |
| Overview | 97 | 1 |
| Safety | 97 | 1 |
| Efficacy | 97 | 1 |
| Hizentra | 98 | 1 |
| Overview | 98 | 1 |
| Safety | 98 | 1 |
| Efficacy | 98 | 1 |
| Pentaglobin | 98 | 1 |
| Overview | 98 | 1 |
| Efficacy | 98 | 1 |
| Safety | 99 | 1 |
| Tegeline | 99 | 1 |
| Overview | 99 | 1 |
| Efficacy in multifocal motor neuropathy | 99 | 1 |
| Safety in multifocal motor neuropathy | 99 | 1 |
| Efficacy in CIDP | 99 | 1 |
| Safety in CIDP | 99 | 1 |
| Global Immunoglobulins Market: Competitive Landscape | 100 | 9 |
| Market Share Analysis: Immunoglobulins | 100 | 1 |
| Baxter International Inc. | 101 | 1 |
| Business Description | 101 | 1 |
| SWOT Analysis | 101 | 1 |
| Biotest | 102 | 1 |
| Business Description | 102 | 1 |
| SWOT Analysis | 102 | 1 |
| Bio Products Laboratory Ltd. | 103 | 1 |
| Business Description | 103 | 1 |
| SWOT Analysis | 103 | 1 |
| CSL Behring LLC | 103 | 1 |
| Business Description | 103 | 1 |
| SWOT Analysis | 104 | 1 |
| Kedrion S.p.A. | 104 | 1 |
| Business Description | 104 | 1 |
| SWOT Analysis | 105 | 1 |
| LFB S.A. | 105 | 1 |
| Business Description | 105 | 1 |
| SWOT Analysis | 105 | 1 |
| Octapharma AG | 106 | 1 |
| Business Description | 106 | 1 |
| SWOT Analysis | 106 | 1 |
| Talecris Biotherapeutics Holdings Corp | 107 | 1 |
| Business Description | 107 | 1 |
| SWOT Analysis | 107 | 1 |
| Grifols S.A. | 108 | 1 |
| Business Description | 108 | 1 |
| SWOT Analysis | 108 | 1 |
| Global Immunoglobulins Market: M&A and Licensing Deals Landscape | 109 | 5 |
| Overview | 109 | 3 |
| R&D Licensing Agreements | 112 | 1 |
| Kedrion Signs Up With Prometic for Access to the Latter s Technologies to Manufacture Hyperimmunes in Europe | 112 | 1 |
| WIBP Enters Into Licensing Agreement with Prometic for the Latter s PPP System to Produce Plasma-Derived Products in China | 112 | 1 |
| Co-Development Agreements | 113 | 1 |
| Baxter Collaborates With Halozyme Baxter for a Subcutaneous Route of Administration of GAMMAGARD LIQUID 10% | 113 | 1 |
| Global Immunoglobulins Market: Appendix | 114 | 8 |
| Market Definitions | 114 | 1 |
| Abbreviations | 114 | 2 |
| Research Methodology | 116 | 5 |
| Coverage | 116 | 1 |
| Secondary Research | 116 | 1 |
| Primary Research | 117 | 1 |
| Therapeutic Landscape | 117 | 1 |
| Epidemiology-based Forecasting | 118 | 1 |
| Market Size by Geography | 119 | 1 |
| Geographical Landscape | 120 | 1 |
| Pipeline Analysis | 120 | 1 |
| Competitive Landscape | 120 | 1 |
| Expert Panel Validation | 120 | 1 |